Vikas A. Gupta
YOU?
Author Swipe
View article: Profile of NDMM patients who remain progression free at 10 years treated with RVD induction and risk adapted maintenance
Profile of NDMM patients who remain progression free at 10 years treated with RVD induction and risk adapted maintenance Open
Introduction: Multiple myeloma remains incurable despite treatment advances that have significantly improved progression-free survival (PFS) and overall survival (OS). In a recent single-center retrospective analysis of 323 patients with n…
View article: Morphologic leukemia-free state (MLFS) is associated with inferior outcomes in patients with Acute Myeloid Leukemia (AML) treated with front-line azacitidine plus venetoclax
Morphologic leukemia-free state (MLFS) is associated with inferior outcomes in patients with Acute Myeloid Leukemia (AML) treated with front-line azacitidine plus venetoclax Open
Background: Azacitidine plus venetoclax (Aza-Ven) is now standard of care for newly diagnosed acute myeloid leukemia (AML) in patients (pts) ineligible for intensive chemotherapy. Whilst this is better tolerated than intensive induction th…
View article: Multiple myeloma genetic alterations have distinct repertoires and prognostic implications in African and european ancestries
Multiple myeloma genetic alterations have distinct repertoires and prognostic implications in African and european ancestries Open
Introduction: Multiple Myeloma (MM) disproportionately affects Black individuals, where it is 2-3 times more prevalent than in White populations. Prior studies have identified distinct germline risk alleles between Black and White individu…
View article: Negative regulators of survival and proliferation (NRSPs) identified by CRISPR activation studies in multiple myeloma (MM) vs. other neoplasias: Therapeutic implications
Negative regulators of survival and proliferation (NRSPs) identified by CRISPR activation studies in multiple myeloma (MM) vs. other neoplasias: Therapeutic implications Open
Background - Methods: Hundreds of cell lines have been examined by genome-sale CRISPR knockout (KO) studies to identify functional drivers of tumors, but only few lines have been systematically examined with CRISPR activation (CRISPRa). We…
View article: Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience
Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience Open
Four bispecific antibodies (BsAbs) are approved for the treatment of relapsed refractory multiple myeloma (RRMM), but their use is associated with infection risks, requiring mitigation strategies. This single-center retrospective study eva…
View article: Early CD4+ T cell proliferation and chronic T cell engagement impact myeloma outcomes following T cell engager therapy
Early CD4+ T cell proliferation and chronic T cell engagement impact myeloma outcomes following T cell engager therapy Open
View article: Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia
Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia Open
Acute myeloid leukemia (AML) patients exhibit diverse molecular and cytogenetic changes with heterogeneous outcomes. The functionally-derived LSC17 gene expression score has demonstrated strong prognostic significance in retrospective anal…
View article: Another 1q bites the dust
Another 1q bites the dust Open
View article: Feasibility and Safety of Outpatient Model for Administration of Bispecific Antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract
Feasibility and Safety of Outpatient Model for Administration of Bispecific Antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract Open
Implementation of this OP BsAb SUD protocol is feasible with acceptable risk of CRS/ICANS and hospitalization without compromising on safety. The low incidence of CRS/ ICANS with prophylactic tocilizumab and premedication and low hospitali…
View article: <scp>BCL2</scp> inhibition for multiple myeloma and <scp>AL</scp> amyloidosis
<span>BCL2</span> inhibition for multiple myeloma and <span>AL</span> amyloidosis Open
Summary Despite the development of novel treatments, multiple myeloma (MM) and light‐chain (AL) amyloidosis remain incurable diseases. BCL2 inhibitors are a class of drugs under development for plasma cell disorders, with strong data suppo…
View article: Immune-aging is linked to clinical malignancy, racial ancestry, and vaccine responses in myeloma
Immune-aging is linked to clinical malignancy, racial ancestry, and vaccine responses in myeloma Open
View article: In-vitro propagation of citrus: Protocol development for regeneration and multiple shoot induction from nodal segments
In-vitro propagation of citrus: Protocol development for regeneration and multiple shoot induction from nodal segments Open
View article: Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (Ndmm): A Real-World Experience at Two Institutes
Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (Ndmm): A Real-World Experience at Two Institutes Open
View article: Feasibility and Safety of Outpatient Model for Administration of Bispecific Antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract
Feasibility and Safety of Outpatient Model for Administration of Bispecific Antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract Open
View article: Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis
Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis Open
We previously demonstrated that reduced intrinsic electron transport chain (ETC) activity predicts and promotes sensitivity to the B-cell lymphoma 2 (BCL-2) antagonist, venetoclax (Ven), in multiple myeloma (MM). Heme, an iron-containing p…
View article: Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma
Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma Open
View article: Quadruplet therapy for newly diagnosed myeloma: Comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) vs daratumamab with RVD (DRVd) in transplant-eligible patients
Quadruplet therapy for newly diagnosed myeloma: Comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) vs daratumamab with RVD (DRVd) in transplant-eligible patients Open
Lenalidomide, bortezomib and dexamethasone (RVd) has previously been established as standard of care induction therapy for newly diagnosed multiple myeloma (NDMM). More recently, randomized phase 3 data have demonstrated the benefit of the…
View article: Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience
Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience Open
View article: Table S5 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
Table S5 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors Open
Supplementary Table S5 presents multivariate analysis of pooled clinical trial data on R/R MM patients achieving complete response (CR) or better – variables include statin use, t11;14 status, prior lines of therapy, cytogenetic risk.
View article: Table S3 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
Table S3 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors Open
Supplementary Table S3 presents statistical analysis of pooled clinical trial data on R/R MM patient response to venetoclax treatment, comparing t11;14 patients to non-t11;14.
View article: Figure S4 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
Figure S4 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors Open
Supplementary Figure 4 contains BH3 profiling data, and viability assays in cells expressing p53 dominant negative
View article: Data from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
Data from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors Open
The BCL2 inhibitor venetoclax promotes apoptosis in blood cancer cells and is approved for treatment of chronic lymphocytic leukemia and acute myeloid leukemia. However, multiple myeloma cells are frequently more dependent on MCL-1 for sur…
View article: Figure S5 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
Figure S5 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors Open
Supplementary Figure 5 contains viability data and PUMA expression data from PBMCs
View article: FIGURE 1 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
FIGURE 1 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors Open
Statins significantly improve responses in a retrospective analysis of venetoclax clinical trials in R/R multiple myeloma. Results of patients with R/R multiple myeloma from venetoclax clinical trials receiving the standard therapy of Dex …
View article: Figure S2 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
Figure S2 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors Open
Supplementary Figure 2 contains PFS data from venetoclax clinical trials in MM
View article: FIGURE 5 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
FIGURE 5 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors Open
Activation of stress pathways is induced by pitavastatin and the ISR inhibitor, ISRIB, partially rescues from statin-mediated sensitization of BH3 mimetics. A, ATF4 and stress activated factors were assessed across our panel of cell…
View article: Figure S7 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
Figure S7 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors Open
Supplementary Figure 7 contains data comparing pitavastatin with simavastatin in western blots (panel A) and BH3 profiling data with pitavastatin (panel B).
View article: Figure S10 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
Figure S10 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors Open
Supplementary Figure 10 contains additional data on ISR-dependent changes in protein synthesis rates and viability.
View article: Figure S2 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
Figure S2 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors Open
Supplementary Figure 2 contains PFS data from venetoclax clinical trials in MM
View article: Figure S3 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
Figure S3 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors Open
Supplementary Figure 3 contains additional viability assay data and synergy contour plots